- Home
- GDYN vs ALLO Comparison
GDYN vs ALLO Comparison
Compare GDYN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | ALLO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 597.7M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GDYN | ALLO |
|---|---|---|
| Price | $7.64 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $10.67 | $8.35 |
| AVG Volume (30 Days) | 858.5K | ★ 4.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 34.09 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.84 | $142,416.42 |
| P/E Ratio | $385.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.11 | $1.04 |
| 52 Week High | $10.21 | $4.46 |
Technical Indicators
Market Signals| Indicator | GDYN | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 35.00 |
| Support Level | $7.61 | $1.59 |
| Resistance Level | $8.15 | $2.22 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 17.75 | 0.00 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).